Lipid-lowering efficacy and safety of ezetimibe combining simvastatin in patients with coronary heart disease and hyperlipidemia
BI Lei
CAO Dan-yang
WANG Wei
ZHU Li-zhang
Abstract：Objective To review the efficacy and safety of ezetimibe combining simvastatin in patients with coronary heart disease and hyperlipidemia. Methods The patients (n=60) were chosen from Jun. 2011 to Aug. 2013, and then randomly divided into control group and treatment group (each n=30). The levels of total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and triglyceride (TG) were detected and adverse reactions were observed and recorded. Results The levels of TC, TG and LDL-C decreased in control group and treatment group (all P<0.05) after treatment. Compared with control group after treatment, TC [(4.10±1.24) mmol/L], TG [(1.64±0.75) mmol/L] and LDL-C [(2.33±0.75) mmol/L] decreased in treatment group (all P<0.05). After treatment, control rate of LDL-C was 46.7%in control group and 76.7%in treatment group (P<0.05). Conclusion Ezetimibe combining simvastatin can improve lipid-lowering efficacy, and the curative effect is superior to single simvastatin with less adverse reactions.
Keywords：EzetimibeSimvastatinCoronary heart diseaseHyperlipidemia
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 422-423,427 )